Open AccessRetrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia
Author(s) -
Srđan Verstovšek,
Ruben A. Mesa,
Moshe Talpaz,
JeanJacques Kiladjian,
Claire Harrison,
Stephen T. Oh,
Alessandro M. Vannucchi,
Raajit K. Rampal,
Bart L. Scott,
Sarah Buckley,
Adam Craig,
Karisse RomanTorres,
John Mascarenhas
Publication year - 2021
Publication title -
haematologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.782
H-Index - 142
eISSN - 1592-8721
pISSN - 0390-6078
DOI - 10.3324/haematol.2021.279415
Subject(s) - medicine , ruxolitinib , myelofibrosis , adverse effect , retrospective cohort study , clinical endpoint , population , gastroenterology , surgery , randomized controlled trial , bone marrow , environmental health
Thrombocytopenia is common in patients with myelofibrosis and is a well-established adverse prognostic factor. Both of the approved Janus kinase (JAK) inhibitors, ruxolitinib and fedratinib, can worsen thrombocytopenia and have not been evaluated in patients with severe thrombocytopenia (